CITIC International raised the target price of RemeGen to 136 yuan and adjusted the revenue forecast for this year and next year

AASTOCKS
2026.01.15 02:54

Jiaoyin International published a research report stating that RemeGen (09995.HK) has reached an exclusive licensing agreement with AbbVie (ABBV.US) for RC148, with the latter obtaining exclusive rights for the development, production, and commercialization of RC148 outside Greater China. RemeGen will receive a $650 million upfront payment, up to $4.95 billion in milestone payments, and a double-digit percentage tiered sales commission.

The firm believes that this transaction has a limited short-term direct impact on similar target products that have already gone abroad, such as Kangfang (09926.HK) and SanSheng (01530.HK), considering their first-mover advantage in clinical progress.

The firm raised RemeGen's revenue forecast for 2026 to 2027 and increased the target price to 136 yuan. It is optimistic about the progress of Tislelizumab and Vidutolimod in overseas registration studies in 2026, as well as the progress of early-stage products in more indications

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer